Compare Novartis with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs WOCKHARDT - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS WOCKHARDT NOVARTIS/
WOCKHARDT
 
P/E (TTM) x 1,964.2 -88.2 - View Chart
P/BV x 26.1 2.0 1,335.1% View Chart
Dividend Yield % 1.7 0.0 85,784.5%  

Financials

 NOVARTIS   WOCKHARDT
EQUITY SHARE DATA
    NOVARTIS
Mar-19
WOCKHARDT
Mar-18
NOVARTIS/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs9801,012 96.8%   
Low Rs600532 112.9%   
Sales per share (Unadj.) Rs198.7355.9 55.8%  
Earnings per share (Unadj.) Rs21.0-60.3 -34.8%  
Cash flow per share (Unadj.) Rs22.3-46.8 -47.6%  
Dividends per share (Unadj.) Rs10.000.01 100,000.0%  
Dividend yield (eoy) %1.30 97,677.5%  
Book value per share (Unadj.) Rs307.5257.8 119.3%  
Shares outstanding (eoy) m24.69110.63 22.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.02.2 183.3%   
Avg P/E ratio x37.7-12.8 -294.3%  
P/CF ratio (eoy) x35.5-16.5 -215.1%  
Price / Book Value ratio x2.63.0 85.8%  
Dividend payout %47.70 -287,473.7%   
Avg Mkt Cap Rs m19,50885,379 22.8%   
No. of employees `0000.66.3 9.3%   
Total wages/salary Rs m1,1719,371 12.5%   
Avg. sales/employee Rs Th8,445.46,295.0 134.2%   
Avg. wages/employee Rs Th2,015.71,498.3 134.5%   
Avg. net profit/employee Rs Th891.0-1,066.3 -83.6%   
INCOME DATA
Net Sales Rs m4,90739,369 12.5%  
Other income Rs m7831,202 65.1%   
Total revenues Rs m5,68940,571 14.0%   
Gross profit Rs m12318 671.0%  
Depreciation Rs m321,495 2.1%   
Interest Rs m162,555 0.6%   
Profit before tax Rs m858-2,830 -30.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m340257 132.3%   
Profit after tax Rs m518-6,669 -7.8%  
Gross profit margin %2.50 5,384.0%  
Effective tax rate %39.6-9.1 -436.5%   
Net profit margin %10.6-16.9 -62.3%  
BALANCE SHEET DATA
Current assets Rs m8,05533,796 23.8%   
Current liabilities Rs m1,85026,917 6.9%   
Net working cap to sales %126.417.5 723.7%  
Current ratio x4.41.3 346.7%  
Inventory Days Days4579 56.7%  
Debtors Days Days3489 38.0%  
Net fixed assets Rs m15039,664 0.4%   
Share capital Rs m123553 22.3%   
"Free" reserves Rs m7,46927,968 26.7%   
Net worth Rs m7,59228,522 26.6%   
Long term debt Rs m021,731 0.0%   
Total assets Rs m9,82481,620 12.0%  
Interest coverage x54.9-0.1 -51,101.2%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.50.5 103.5%   
Return on assets %5.4-5.0 -107.8%  
Return on equity %6.8-23.4 -29.2%  
Return on capital %11.5-7.7 -149.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m589,807 0.6%   
Fx outflow Rs m1,3261,789 74.2%   
Net fx Rs m-1,2698,019 -15.8%   
CASH FLOW
From Operations Rs m-1,943684 -283.9%  
From Investments Rs m2,7426,302 43.5%  
From Financial Activity Rs m-298-7,695 3.9%  
Net Cashflow Rs m501-664 -75.5%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 2.3 87.0%  
FIIs % 1.6 7.7 20.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 21.5 15.4 139.6%  
Shareholders   41,647 67,757 61.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   VENUS REMEDIES  NEULAND LABS  PIRAMAL ENTERPRISES  J.B.CHEMICALS  SHASUN PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Apr 20, 2021 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS